What is the lowest dose of Wegovy, and why does it matter?

The myth: 0.25mg is the 'weak' dose people skip past

A common assumption is that the lowest Wegovy dose is something to rush through — a formality before reaching the dose that 'actually works'. That framing misses the point. The 0.25mg weekly dose is not a reduced-strength treatment, but a deliberate physiological introduction. Semaglutide slows the rate at which the stomach empties and acts on appetite signals in the brain. When the body encounters that effect for the first time, nausea, constipation and digestive discomfort are common. Starting low and titrating gradually is the mechanism by which most people avoid the worst of those side effects.

The NHS medicines page for semaglutide sets out the full titration pathway: 0.25mg for the first four weeks, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg as the standard maintenance dose. Each step is typically held for around four weeks. The prescriber decides whether you are ready to move up, if side effects are still significant, staying at the current dose longer is clinically appropriate. Skipping doses or self-escalating is not recommended and is something to raise with your prescriber rather than decide alone.

For a fuller picture of how the whole dosing pathway fits together, the complete guide to Wegovy doses on our site covers each strength in detail.

Why the 0.25mg dose rarely produces dramatic results on its own

There is real and understandable frustration when the scales do not move much in the first month. At 0.25mg, that is almost always expected. The clinical trial data for Wegovy (including the STEP 1 study published in the New England Journal of Medicine, which found around 15% average body weight reduction over 68 weeks) was measured at the 2.4mg maintenance dose, not at the starter level. Weight loss at 0.25mg is possible but not the primary purpose of that phase.

The body needs time to adapt. Appetite suppression tends to become more noticeable as the dose increases, and most clinical benefit accumulates over months rather than weeks. People who interpret a quiet first month as the medicine 'not working' sometimes stop early, which means they never reach the dose range where meaningful results occur. Sticking with the schedule (while being honest with your prescriber about how you are tolerating it) is what the evidence supports.

If you are curious about the evidence on weight loss even at the starting level, what the data shows about losing weight on the lowest Wegovy dose explores that in more depth. And if you have wondered whether staying at 0.25mg longer-term is an option, whether remaining on the lowest dose is clinically practical covers the considerations a prescriber would weigh.

The UK dosing picture in 2025 and 2026: what has changed

Until recently, 2.4mg was the ceiling for Wegovy. In January 2026 the MHRA licensed a higher 7.2mg maintenance dose, initially administered as three 2.4mg injections per week, and then, from 14 April 2026, available as a dedicated single-dose 7.2mg pen approved specifically for adults with a BMI of 30 or above. Trial data at this higher dose showed around 20.7% average weight loss over 72 weeks, bringing it closer to the results seen with tirzepatide in head-to-head comparisons.

The 0.25mg starting dose remains unchanged regardless of which maintenance target you are working towards. Whether you end up at 2.4mg or 7.2mg, your prescriber will still begin at the bottom and move upward at a pace your body can manage. The route is the same; the destination may differ based on your clinical profile and how you respond.

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. That eligibility assessment (including which dose trajectory makes sense for you) is part of what a prescriber considers. You can read more about how prescribers decide which Wegovy dosage suits you, or explore the broader treatment options on our weight loss overview.

Wegovy is a prescription-only medicine. For context on how costs vary across the titration schedule in private care, our guide to where and how to get Wegovy in the UK covers what to look for in a regulated provider. If you would like to explore whether treatment might be suitable, check your eligibility with our prescribers through a free consultation.